Diligence memo · auto-generated · as of July 2, 2026
NRX Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
NRX Pharmaceuticals, Inc. operates in Biotechnology, based in WILMINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NRX Pharmaceuticals, Inc. has raised $3.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.5M on 2025-01-27.
Most recent recorded round closed around 2025-01-27.
Valuation (modeled)modeled
Provath models NRX Pharmaceuticals, Inc. at approximately $12M (range $2.5M–$28M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.70× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 37% of Biotechnology peers (4293 compared).
Modeled value ranks above 21% of those peers.
Closest niche peers: Carna Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp., Synlico Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.